Particulars |
Unaudited Results |
Audited Results |
Consolidated Results |
| Nine Months Ended |
Three Months Ended |
The Year Ended |
The Year Ended |
| 31.12.2006 |
31.03.2007 |
31.03.2006 |
31.03.2007 |
31.03.2006 |
31.03.2007 |
31.03.2006 |
| Net Sales/Income from Operations |
14469.6 |
5327.6 |
4630.4 |
19797.2 |
14722.0 |
22502.2 |
16955.0 |
| Other Income |
279.0 |
152.3 |
63.8 |
431.3 |
103.3 |
495.3 |
535.4 |
| Total income |
14748.6 |
5479.9 |
4694.2 |
20228.5 |
14825.3 |
22997.5 |
17490.4 |
| Expenditure |
|
|
|
|
|
|
|
| a. (Increase)/Decrease in Stock in
Trade |
(583.6) |
(160.6) |
(147.1) |
(744.2) |
(275.3) |
(890.5) |
(518.3) |
| b. Consumption of Raw Material |
8747.5 |
3216.6 |
2785.8 |
11964.1 |
9026.8 |
12594.7 |
10054.7 |
| c. Staff Cost |
808.8 |
320.0 |
202.5 |
1128.8 |
792.2 |
1504.2 |
1024.2 |
| d. Other Expenditure |
3362.5 |
1300.0 |
1073.4 |
4662.5 |
3435.2 |
6274.1 |
4619.4 |
| Total expenditure |
12335.2 |
4676.0 |
3914.6 |
17011.2 |
12978.9 |
19482.5 |
15180.0 |
| Profit before depreciation,
interest & tax |
2413.4 |
803.9 |
779.6 |
3217.3 |
2046.6 |
3515.0 |
2310.4 |
| Interest |
157.6 |
29.7 |
119.6 |
187.3 |
606.4 |
453.6 |
604.1 |
| Depreciation |
455.6 |
262.8 |
133.4 |
718.4 |
511.4 |
997.1 |
721.3 |
| Profit before taxation |
1800.2 |
511.4 |
526.6 |
2311.6 |
929.0 |
2064.3 |
985.0 |
| Provision for Taxation |
|
|
|
|
|
|
|
| a. Current Tax |
158.6 |
21.9 |
54.0 |
180.5 |
90.1 |
203.4 |
128.4 |
| b. MAT credit entitlement |
-54.6 |
-90.8 |
-80.9 |
-145.4 |
-80.9 |
-145.4 |
-80.9 |
| c. Deferred Tax |
192.9 |
-233.5 |
112.9 |
-40.6 |
158.8 |
-40.6 |
159.0 |
| d. Fringe Benefit Tax |
2.8 |
1.1 |
0.9 |
3.9 |
2.8 |
3.9 |
2.8 |
| e. Tax adjustments of previous
years |
-9.2 |
31.6 |
64.4 |
22.4 |
64.5 |
22.4 |
64.6 |
|
Total tax |
290.5 |
-269.7 |
151.3 |
20.8 |
235.3 |
43.7 |
273.9 |
| Profit before minority interest |
- |
- |
- |
- |
- |
2020.6 |
711.1 |
| Minority Interest |
- |
- |
- |
- |
- |
-11.0 |
-14.1 |
| Net Profit |
1509.7 |
781.1 |
375.3 |
2290.8 |
693.7 |
2009.6 |
697.0 |
| Paid-up Equity Share Capital (Face
value Rs. 5 per share) |
266.7 |
266.7 |
266.4 |
266.7 |
266.4 |
266.7 |
266.4 |
| Reserves excluding Revaluation
Reserve |
|
|
|
9,020.6 |
8,787.8 |
8,587.5 |
7882.1 |
| Basic Earnings per share (Rs.)
(not annualised) |
28.33 |
14.64 |
7.05 |
42.98 |
13.22 |
37.70 |
13.28 |
| Diluted Earnings per share (Rs.) |
22.64 |
11.56 |
6.44 |
34.51 |
12.46 |
30.27 |
12.52 |
| Aggregate of non-promoters
Shareholding |
|
|
|
|
|
|
|
| a. Number of Shares |
|
|
|
23,636,405 |
23,557,656 |
|
|
| b. Percentage of Shareholding |
|
|
|
44.31 |
44.2 |
|
|
|
|
| Notes: |
| 1. |
The above audited Quarterly Results as reviewed by the Audit Committee have been approved by the Board at its meeting held on
June 30, 2007. |
| 2. |
Investor complaints pending at the beginning of the fourth quarter: Nil, received: 56, resolved:
56 and lying unresolved at the end of the quarter: Nil. |
| 3. |
The consolidated Quarterly Results include the results of subsidiary companies and joint venture companies accounted in accordance
with accounting principles as defined in Accounting Standards 21 and 27 issued by the Institute of Chartered Accountants of India. |
|
4. |
The
Board recommends dividend @50%on the equity share capital of the Company i.e Rs.2.50 per share subject to approval of members. |
| 5. |
Keeping
in view the Company's business model of vertical integration, the management reviewed the reporting of its financial results under one segment and accordingly the Company reported its entire results under one segment viz. 'Pharmaceutical Products'. |
| 6. |
F.O.B value of exports is Rs.10952.9 Millions (previous year Rs.8163.3 Millions). |
| 7. |
During the quarter, a Step down subsidiary "Auro Healthcare (Nigeria) Limited" has been formed. |
| 8. |
During the quarter the operations of Aurobindo (HK) Limited, the wholly owned subsidiary were discontinued |
| 9. |
Pursuant to the approval of the Shareholders of the Company in their Meeting held on February 20, 2007, the Honourable High Court at Judicature at Hyderabad vide its Order passed on June 21, 2007 sanctioned the Scheme of Arrangement (Scheme) under Section 391 to 394 read with Section 78 and Section 100 of The Companies Act, 1956 between APL Life Sciences Limited (APL Life
Sciences) and Senor Organics Pvt. Ltd. (Senor), both wholly owned subsidiaries of the Company with the Company with effect from April 1, 2006, and confirmed the utiliazation of Securities Premium Account towards adjustment of the reduction in the carrying value of certain assets. Implementing the said Court
Order, the aggregate reduction of Rs. 1795.4 million has been debited to Securities Premium Account. Further, the difference between the amounts of net assets taken over by the Company over the value of investments in Senor amounting to Rs. 0.7million has also been debited to the Securities Premium Account. |
| 10. |
Premium on redemption of USD 260 Million zero coupon Foreign Currency Convertible Bonds is contingent in nature, since its outcome is dependant on uncertain future events. |
| 11. |
The current year figure includes those relating to transferor companies viz. APL Life Sciences and Senor and therefore the figures of the Previous Year are not comparable with those of the Current year. Further, the figures of the Previous Year have been regrouped, wherever necessary. |
|
| |
|
For and on behalf of the Board |
|
